Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours

ABSTRACT: BACKGROUND: Lanreotide is a long-acting somatostatin analogue with proven antitumour effects against well-differentiated (WD) gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). However, there are no globally established prognostic factors associated with the efficacy of lanreotide a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yong-il, Yoo, Changhoon, Oh, Seung Jun, Lee, Sang Ju, Kang, Junho, Hwang, Hee-Sang, Hong, Seung-Mo, Ryoo, Baek-Yeol, Ryu, Jin-Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295884/
https://www.ncbi.nlm.nih.gov/pubmed/32542576
http://dx.doi.org/10.1186/s13550-020-00651-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295884/
https://www.ncbi.nlm.nih.gov/pubmed/32542576
http://dx.doi.org/10.1186/s13550-020-00651-z

Ejemplares similares